Skip to main content

Caelum Biosciences to be acquired by division of AstraZeneca in $150M deal

The deal's value could grow by up to another $350 million if a series of product development milestones are met.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.